Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)

NCT03201185 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

194

Enrollment

OTHER

Sponsor class

Conditions

Transcatheter Aortic Valve Replacemen
Angiotensin-Converting Enzyme Inhibitors

Interventions

DRUG: Ramipril

Sponsor

Hospital Clínico Universitario de Valladolid